GB Patent

GB1356763A — Substituted benzimidazole derivatives

Assigned to Merck and Co Inc · Expires 1974-06-12 · 52y expired

What this patent protects

1356763 2 - Benzo(heterocyclic)ethyl benzimidazoles and derivatives thereof MERCK & CO Inc 18 April 1972 [21 April 1971] 17917/72 Heading C2C [Also in Division C4] Novel compounds of the Formula I wherein m is 0, 1 or 2, n is 0 or 1, each R is C 1-5 alkyl, alkoxy, haloalkox…

USPTO Abstract

1356763 2 - Benzo(heterocyclic)ethyl benzimidazoles and derivatives thereof MERCK & CO Inc 18 April 1972 [21 April 1971] 17917/72 Heading C2C [Also in Division C4] Novel compounds of the Formula I wherein m is 0, 1 or 2, n is 0 or 1, each R is C 1-5 alkyl, alkoxy, haloalkoxy or alkylthio, C 3-6 cycloalkoxy, C 2-6 alkenyl, or halogen or when m is 2 the R groups together form a methylene dioxy group; R 1 is hydrogen or C 1-5 alkyl; each R 2 is hydrogen or hydroxyl; X is carbonyl; A is oxygen, sulphur, nitrogen, imino, methylene or methine; the dotted lines indicate that a double bond is located at one of the two positions available between A and N with a hydrogen atom attached to N if valency considerations require it; with the provisos that when n is 0, A is not hydrogen or imino, and that when n is 0 and A is oxygen or sulphur at least one m is not 0; and acid addition salts thereof are prepared (a) by reacting the compounds and wherein R, R<SP>1</SP>, R 2 and m are as defined above Z is a carboxylic acid group, an aldehyde or Schiff base derivative thereof, or a nitrile, carboxylic ester, carboximidic ester or carboxylic amide group, and Z 1 is a group of the type defined for Z or is a group of the Formula IV wherein R, X, A, m and n and the dotted lines are as defined above and when Z 1 is a group of the type defined for Z reacting the intermediate of the formula wherein A* is oxygen or sulphur, and then closing the ring; and (b) reacting the above compound of Formula IV when Z is cyano with or when Z is other than cyano with to produce Various [2R,3R] - 2,3 - dihydroxy - 3 - (6- substituted - 2 - benzothiazolyl) - propion - [2- amino-4(5)-methoxy]anilides may be prepared by acetylation of the sodium salt of [2R,3R]-2, 3 - dihydroxy - 3 - (6 - substituted - 2 - benzothiazolyl propionic acid to yield the sodium salt of [2R,3R] - 2,3 - diacetoxy - 3 - (6 - substituted- 2-benzothiazolyl propionic acid which on treatment with 4-methoxy-o-phenylene diamine in the presence of acid and a dehydrating agent yields [2R,3R] - 2,3 - diacetoxy - 3 - (6 - substituted - 2 - benzothiazolyl) - propion - [2 - amino- 4(5)-methoxy]-anilide which on treatment with sodium methoxide yields the required compound. The sodium salt of [2R,3R]-2,3-dihydroxy-3- (6 - methoxy - 2 - benzothiazolyl)propionic acid may be prepared by reacting 2-amino-5-methoxythiophenol with L-diacetyl tartaric anhydride to yield [2R,3R]-2,3-diacetoxy-3-(6-methoxy-2-benzothiazolyl) propionic acid which was converted to its ammonium salt and hydrolsyed with sodium methoxide to the required compound. Various substituted 2-(#-cyanoethyl)benzimidazoles may be prepared by reacting the appropriate o-phenylenediamine with methyl-3-cyanopropyl carboximidate hydrochloride. Various ethyl - 3 - benzimidazolyl - (2) - propionimidate dihydrochlorides substituted in the benzimidazole ring may be prepared by reacting the appropriate 2-(#-cyanoethyl)benzimidazole with ethanol and hydrogen chloride in anhydrous conditions. [2R,3R] - 2,3 - Dihydroxy - 3 - [2 - 4(3H)- quinazolinonyl] - propion - [2 - amino - 4(5). methoxy]-anilide and various derivatives substituted in the 7-position of the quinazoline ring may be prepared by reaction of 4-methoxy-ophenylene diamine with the appropriate [2R, 3R] - 2,3 - dihydroxy - 3 - [2 - 4(3H) - quinazolinonyl]propionic acid which in turn is prepared by treatment of a [αR,#R]-diacetyltartar-2-carbamoyl anilide with sodium hydroxide, which anilide is prepared by treatment of an anthranilamide with L-diacetyl tartaric anhydride. Pharmaceutical compositions of the compounds I show antiviral activity when administered orally, parenterally, topically or as an oral or nasal spray with the usual excipients.

Drugs covered by this patent

Patent Metadata

Patent number
GB1356763A
Jurisdiction
GB
Classification
Expires
1974-06-12
Drug substance claim
No
Drug product claim
No
Assignee
Merck and Co Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.